Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Equivalents (2020 - 2023)

Historic Cash & Equivalents for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $466.4 million.

  • Cullinan Therapeutics' Cash & Equivalents fell 1902.78% to $466.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $466.4 million, marking a year-over-year decrease of 1902.78%. This contributed to the annual value of $156.2 million for FY2022, which is 16123.73% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Cash & Equivalents of $466.4 million as of Q3 2023, which was down 1902.78% from $491.8 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Cash & Equivalents registered a high of $611.0 million during Q2 2022, and its lowest value of $59.8 million during Q4 2021.
  • Its 4-year average for Cash & Equivalents is $341.5 million, with a median of $352.8 million in 2022.
  • Per our database at Business Quant, Cullinan Therapeutics' Cash & Equivalents crashed by 6446.21% in 2021 and then skyrocketed by 39405.68% in 2022.
  • Cullinan Therapeutics' Cash & Equivalents (Quarter) stood at $168.2 million in 2020, then crashed by 64.46% to $59.8 million in 2021, then soared by 161.24% to $156.2 million in 2022, then skyrocketed by 198.68% to $466.4 million in 2023.
  • Its last three reported values are $466.4 million in Q3 2023, $491.8 million for Q2 2023, and $390.7 million during Q1 2023.